1Speir E, Epstein SE. Inhibition of smooth muscle cell proliferation by an antisense oligodeoxynucleotide targeting the message rRNA encoding proliferating cell nuclear antigen. Circulation, 1992, 86: 538～544
2Morishita G, Gibbous GH, Haneda Y, et al. Pharmacokinetics of antisence oligodeoxyribonneleotides (cyclin B1 and CDC2 kinase) in the vessel wall in vivo: enhanced therapetic utility for restenesis by HVJ- liposome delivery. Gene, 1994,4:13 ～ 18
3Chang MW, Barr E, Lu MM, et al.Adenovirus - mediated over- expression of the cyclin/cyclin- dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest,1995,96(5) :2260 ～ 2268
5Fuluda N, Kulso A, Watanabe Y, et al.Antisense oligedeoxynucleotide complementary to platelet - derived growth factor A - chain messenger RNA inhibits the arterial proliferation in spontaneously hypertensive rats without altering their blood pressures. J Hypertens, 1997,15(10):1123～ 1136
6Yukawa H, Miyatake SI, Saiki M, et al.In vitro growth suppression of vascular smooth muscle cells using adenovirusmediated gene transfer of a truncated form of fibroblast growth factor receptor.Atheroscleresis, 1998, 141 ( 1 ): 125 ～132
7Tio RA, Isner JM, Walsh K, et al. Gene therapy to prevent restenosis, the Boston experienee. Semin Interv Cardiol, 1998,3(3 ～ 4) :205 ～ 210
8Frey A, Schneider- Rasp S, Marienfeld U, et al. Biochemical and functional characterization of nitric oxide synthase Ⅲ gene transfer using a replication - deficient adenoviral vector. Biochem Pharmacol, 1999,58(7): 1155 ～ 1166
9Dulak J, Jozkowicz A, Guevara I, et al.Gene transfer of vascular endothelial growth factor and endothelial nitric oxide synthase- implications for gene therapy in cardiovascular diseases. Pol J Pharmacol, 1999,51(3) :233 ～ 241
10Nabel EG, Plautz G, Boyce FM, et al.Recombinant gene expression in vivo within endothelial cells of the arterial wall. Science, 1989,244:1342～1344
